Outlines the main approaches in the development of novel antiasthma treatments. Improvement in existing classes of drugs; Identification of new compounds able to interfere with the complex network of proinflammatory mediators, cytokines chemokines and adhesion molecules involved in the pathogenesis of asthma; Utilization of new forms of immunotherapy aimed at blocking the unbalanced Th2 response which characterizes the pathophysiology of asthma.